ReviewRomanian journal of ophthalmology
Transepithelial photorefractive keratectomy - an analysis of the solutions offered by the industry nowadays.
Review in Romanian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical outcomes and safety of preservative-free diclofenac sodium eye drops in SPT-assisted transepithelial photorefractive keratectomy.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To review and compare the current commercial solutions for transepithelial photorefractive keratectomy (TransPRK) offered by leading excimer laser manufacturers-SCHWIND eye-tech-solutions (AMARIS with SmartPulse), Alcon (WaveLight EX500), and Bausch + Lomb Technolas (TENEO 317), with a focus on technology, treatment protocols, and clinical outcomes. Background: TransPRK, a no-touch surface ablation technique, eliminates mechanical or alcohol-based epithelial removal by using the excimer laser to ablate both epithelium and stromal tissue in a single step. This approach offers advantages, including lower epithelial trauma, reduced risk of infection, and faster epithelial healing. Industry innovation has significantly improved TransPRK outcomes through refined epithelial mapping, high-speed ablation, and advanced eye-tracking systems.All three platforms-SCHWIND AMARIS, WaveLight EX500, and Technolas TENEO-offer effective TransPRK capabilities, each with distinctive advantages. SCHWIND currently leads in terms of surface quality and early visual recovery due to SmartPulse Technology. WaveLight EX500 provides high-speed ablation and robust platform integration, while Technolas TENEO offers customizable epithelial profiles and a user-friendly interface. Conclusion: In summary, modern TransPRK systems provide safe, effective, and increasingly customizable options for correcting myopia and astigmatism. The choice between platforms depends on a range of factors, including surgical goals, patient profile, available technology, and the surgeon's familiarity with the system. As laser platforms continue to evolve, further innovations in epithelial mapping, real-time ablation control, and surface smoothing may continue to enhance the outcomes and expand the indications for TransPRK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.